Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA reports medical-technology developments tied to the Genio system, its patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea. Company news commonly covers financial and operating results, U.S. commercialization activity, regulatory status, manufacturing capacity, reimbursement references, investor conference participation, and the development and commercialization of OSA treatment alternatives.
Nyxoah also publishes regulated information for its Euronext Brussels and Nasdaq securities, including transparency notifications, shareholder-meeting materials, voting-right disclosures, and bond-related capital-structure notices.
Nyxoah (Nasdaq:Euronext: NYXH) convenes an extraordinary shareholders’ meeting on July 9, 2026 at 2:00 p.m. CET at its registered office.
Key agenda items include renewing the board’s authorization to increase share capital for five years and granting powers to the notary. Attendance requires registration by the June 25, 2026 record date and confirmation by July 3, 2026. Shareholders may vote by mail or proxy and follow the meeting via non-voting videoconference.
Nyxoah (Nasdaq/Euronext: NYXH) published multiple transparency notifications on recent shareholding changes as required under Belgian law.
Notifications cover Robert Taub/Robelga (14.50% including warrants), Pierre‑Edouard Stérin/B.A.D. 21 (7.23%), Cochlear Limited (5.85%), Gilde Healthcare (below 3%), and Bank of America around the 3% threshold via voting rights and financial instruments.
Nyxoah (Nasdaq: NYXH) received $15 million (€13.8 million) from the second tranche of its European Investment Bank loan facility, described as non-dilutive debt funding.
This drawdown brings total new capital raised in June 2026 to about $110 million, supporting the U.S. commercial launch of Genio, R&D, and manufacturing scale-up.
Nyxoah (Nasdaq: NYXH) announced that its Genio® hypoglossal nerve stimulation therapy for Obstructive Sleep Apnea won the Prix Galien UK 2026 Award for Best Medical Technology in London.
The award follows FDA approval, U.S. commercial launch, new financing for U.S. expansion, and growing international adoption of Genio.
Nyxoah (Nasdaq: NYXH) reported updated share and voting rights information following the issuance of 55,232,558 new shares linked to its underwritten public offering in the United States.
The company now has share capital of EUR 7,073,687 and 99,926,284 ordinary shares, all carrying voting rights.
Nyxoah (Nasdaq: NYXH) announced $110 million in aggregate financings to support the U.S. commercial launch of its Genio system for obstructive sleep apnea.
The company completed a $95 million equity financing and expects a $15 million second tranche from its European Investment Bank loan by end of June 2026, backing an accelerated U.S. commercialization with 40 sales reps already in place.
Nyxoah (Nasdaq: NYXH) closed an underwritten public offering of 55,232,558 ordinary shares at $1.72 (EUR 1.48) per share, raising approximately $95.0 million (EUR 81.9 million) in gross proceeds.
Nyxoah plans to fund U.S. commercialization, Genio system R&D and cost reductions, international launches, clinical data generation, and general corporate purposes. It also intends to draw EUR 13.8 million from the second tranche of its European Investment Bank loan in Q2 2026.
Nyxoah (NASDAQ:NYXH) priced a $95 million underwritten public offering of 55,232,558 ordinary shares at $1.72 (EUR 1.48) per share, with no selling shareholders and a 30‑day option for 8,284,883 additional shares.
Closing is expected around June 9, 2026. According to Nyxoah, net proceeds will fund U.S. commercialization, Genio system R&D and upgrades, international commercialization and clinical data generation, and general corporate purposes. The company also plans to draw EUR 13.8 million from the second tranche of its European Investment Bank loan in Q2 2026.
Nyxoah (Nasdaq: NYXH) launched a proposed underwritten public offering of ordinary shares in the United States, with no selling shareholders participating.
The company may grant underwriters a 30-day option for up to 15% additional shares and plans to use proceeds for U.S. and international commercialization of the Genio system, R&D, clinical data generation, and general corporate purposes.
Nyxoah (Nasdaq: NYXH) announced a leadership transition process aimed at accelerating long-term value creation and U.S. commercial growth for its Genio system for Obstructive Sleep Apnea.
The Board has launched a search for a new U.S.-based CEO, while current CEO Olivier Taelman will remain fully engaged and lead daily operations during the transition.